Zacks Research Issues Positive Forecast for ResMed Earnings

ResMed Inc. (NYSE:RMD) – Zacks Research upped their Q1 2026 earnings estimates for shares of ResMed in a research note issued on Friday, October 17th. Zacks Research analyst Team now anticipates that the medical equipment provider will earn $2.47 per share for the quarter, up from their prior forecast of $2.46. The consensus estimate for ResMed’s current full-year earnings is $9.47 per share. Zacks Research also issued estimates for ResMed’s Q2 2026 earnings at $2.61 EPS, Q3 2026 earnings at $2.64 EPS, Q4 2026 earnings at $2.65 EPS, FY2026 earnings at $10.37 EPS, FY2027 earnings at $11.08 EPS and Q1 2028 earnings at $3.06 EPS.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, July 31st. The medical equipment provider reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.08. ResMed had a net margin of 27.22% and a return on equity of 25.62%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the prior year, the company posted $2.08 EPS. The company’s quarterly revenue was up 10.2% compared to the same quarter last year.

RMD has been the subject of a number of other research reports. KeyCorp upped their price objective on shares of ResMed from $274.00 to $298.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Royal Bank Of Canada upped their price objective on shares of ResMed from $294.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Piper Sandler increased their target price on shares of ResMed from $248.00 to $270.00 and gave the stock a “neutral” rating in a research report on Friday, August 1st. Mizuho increased their target price on shares of ResMed from $270.00 to $290.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Finally, UBS Group raised shares of ResMed to a “strong-buy” rating in a research report on Tuesday, September 16th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, ResMed presently has a consensus rating of “Moderate Buy” and an average target price of $292.91.

ResMed Trading Up 1.3%

NYSE RMD opened at $271.44 on Monday. ResMed has a 12 month low of $199.92 and a 12 month high of $293.81. The company has a 50-day moving average of $276.88 and a 200-day moving average of $258.14. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.44 and a quick ratio of 2.53. The company has a market cap of $39.61 billion, a P/E ratio of 28.54, a P/E/G ratio of 1.79 and a beta of 0.83.

Hedge Funds Weigh In On ResMed

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Miracle Mile Advisors LLC boosted its holdings in ResMed by 4.9% in the 3rd quarter. Miracle Mile Advisors LLC now owns 1,150 shares of the medical equipment provider’s stock worth $315,000 after acquiring an additional 54 shares during the period. Merit Financial Group LLC boosted its stake in shares of ResMed by 25.0% during the 3rd quarter. Merit Financial Group LLC now owns 1,823 shares of the medical equipment provider’s stock valued at $499,000 after buying an additional 365 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its stake in shares of ResMed by 2.4% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 136,700 shares of the medical equipment provider’s stock valued at $37,419,000 after buying an additional 3,200 shares during the last quarter. Baron Wealth Management LLC boosted its stake in shares of ResMed by 4.3% during the 3rd quarter. Baron Wealth Management LLC now owns 1,545 shares of the medical equipment provider’s stock valued at $423,000 after buying an additional 64 shares during the last quarter. Finally, Diversified Trust Co boosted its stake in shares of ResMed by 5.9% during the 3rd quarter. Diversified Trust Co now owns 1,124 shares of the medical equipment provider’s stock valued at $308,000 after buying an additional 63 shares during the last quarter. Hedge funds and other institutional investors own 54.98% of the company’s stock.

Insiders Place Their Bets

In other ResMed news, General Counsel Michael J. Rider sold 100 shares of the company’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $274.36, for a total value of $27,436.00. Following the completion of the transaction, the general counsel owned 11,327 shares in the company, valued at $3,107,675.72. This represents a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael J. Farrell sold 8,009 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $282.85, for a total value of $2,265,345.65. Following the completion of the transaction, the chief executive officer owned 467,792 shares of the company’s stock, valued at approximately $132,314,967.20. This represents a 1.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,743 shares of company stock worth $5,284,514 in the last 90 days. 0.65% of the stock is owned by company insiders.

ResMed Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, September 18th. Shareholders of record on Thursday, August 14th were issued a $0.60 dividend. The ex-dividend date was Thursday, August 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. This is a boost from ResMed’s previous quarterly dividend of $0.53. ResMed’s dividend payout ratio (DPR) is currently 25.24%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.